Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

MLA

Dimopoulos, M. A.Kastritis, E.Christoulas, D.Migkou, M.and Gavriatopoulou, M.Gkotzamanidou, M.Iakovaki, M.and Matsouka, C.Mparmparoussi, D.Roussou, M.Efstathiou, E.and Terpos, E. Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and of Previous Therapies. Jan. 2010. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..1a2326774b922efa56cd70180b09b430&authtype=sso&custid=ns315887.

APA

Dimopoulos, M. A. K. E. C. D. M. M. and G. M. G. M. I. M. and M. C. M. D. R. M. E. E. and T. E. (2010). Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

Chicago

Dimopoulos, M. A. Kastritis, E. Christoulas, D. Migkou, M. and Gavriatopoulou, M. Gkotzamanidou, M. Iakovaki, M. and Matsouka, C. Mparmparoussi, D. Roussou, M. Efstathiou, E. and Terpos, E. 2010. “Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone with or without Bortezomib: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and of Previous Therapies,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..1a2326774b922efa56cd70180b09b430&authtype=sso&custid=ns315887.